The first batch of Russian Covid-19 vaccine is released to the population | Coronavirus

According to the statement, the first batch of Sputnik V vaccine, developed by the Gamaleya Institute of Epidemiology and Microbiology, passed quality tests and was delivered to the civilian population. The Ministry also says that the actual delivery of the first batches is scheduled for the near future, but does not specify dates.

• VACCINE RACE: meet the main candidates
• VACCINES TESTED IN BRAZIL: understand research

On Friday (4), the deputy director of the Gamaleya institute, Denis Logunov, had already announced that the vaccine could be released to the population this week.

According to Logunov, there is a “broad evidence base that the vaccine is safe” and that safety “was the main prerequisite for its registration.”

A study with preliminary results published in the scientific journal “The Lancet” on day 4 showed that the Russian vaccine for Covid-19 had no adverse effects and induced an immune response.

The Sputnik V vaccine will be launched in conjunction with Phase 3 clinical trials, which will be conducted on 40,000 volunteers, of whom 30,000 will receive the immunizer and 10,000 will receive a placebo (no effect) substance.

The vaccine should have a lighter version for children, Professor Aleksandr Butenko of the Gamalyea National Center for Research in Epidemiology and Microbiology said Tuesday (8).

According to Butenko, only people over 18 years old participate in the tests, but the final product must have an adapted children’s version.

“Children have a different body mass. Of course, a child who weighs 20 pounds definitely needs a lower dose than an adult who weighs 50, 60 or 70 pounds,” the scientist told the Tass news agency.

In an interview with Russian radio Sputnik, the scientist said that the vaccine for children will be lighter and therefore less susceptible to reactions.

“The immune system of a child may not be sufficiently developed as that of an adult. In one way or another, all vaccines have classifications, for children and adults,” he emphasized.

According to the researcher, the documentation to obtain permission from the Russian Ministry of Health to the study of this vaccine in children has not yet been completed. The process is ongoing.

So far, the Russian Covid-19 vaccine is targeting people between the ages of 18 and 60.

In Brazil, the government of Paraná signed an association to develop the Russian vaccine and reported on Friday (4) that the application for registration of the immunizer with the National Sanitary Surveillance Agency (Anvisa) must be made in 10 days. In-country testing should begin in 1 month.